TW EN

scroll

Go Top

Overview

TCTC

1. To attract international pharmaceutical/biotechnology companies to perform clinical trials on GI diseases and H. pylori associated diseases in Taiwan, including trials of new drugs, biomarkers, or diagnostic tests.

2. To establish a clinical and basic medical research center for GI diseases as a platform for collaborative research.

3. To help Taiwan pharmaceutical/biotechnology companies develop new therapeutic drugs and diagnostic modalities in the treatment of GI diseases and H. pylori infection.

4. To support investigator-initiated studies to solve important health problems.

Strengths

TCTC

1. To focus on the antimicrobial susceptibility test, genotypic resistance, eradication efficacy, adverse effects of regimens and the impact of H. pylori eradication on gut microbiota.

2. Clinical trials for the diagnosis and treatment of gastrointestinal diseases.

3. To develop the prevention and screening strategies for gastrointestinal diseases to promote health of people.

Major Achievements

TCTC

International cooperation

  • Our systematic review and meta-analysis showed that the prevalence of antimicrobial resistance in the Asia-Pacific continues increased over time. The Reuters reported this important finding.
  • In 2019, we held a globalH. pylori consensus meeting in Taiwan to developed an important global consensus guideline for H. pylori treatment and gastric cancer prevention.
 

Industry-University-Research Orientation

  • The Vstrip®H. pylori antigen rapid test has been "pre-approved" by the US Food and Drug Administration for its medical device 510(k) pre-market notification permit. This is the first and the only H. pylori antigen rapid test outside the United States that has been approved and marketed by the U.S. FDA.

  • To help publish the introduction of the Covid-19 detection equipment of the TCI CO., Ltd (QVS-96) in Nat Biotechnol 2020. The Taiwan’s self-made medical equipment obtained the Emergency Use Authorization from the US FDA.
 

Social and other aspects

  • The net-work analysis of clinical trials including our randomized trial has confirmed that the quadruple therapy and longer treatment days have better eradication efficacies forH. pylori infection.
  • Our randomized trial found that the empirical guided therapy is not inferior to susceptibility guided therapy for treatment of refractoryH. pylori infection. This is the first randomized trial in the world to explore this issue.
 

Important notes of the consortium

In 2017

  • Taiwan Clinical Trial Consortium for Gastrointestinal Disease and Helicobacter was established
  • Our study showed the prevalence of antimicrobial resistance in the Asia-Pacific continues increased over time. (Lancet Gastroenterol Hepatol 2017)

In 2018

  • Our net-work analysis of clinical trials including our randomized trial has confirmed that the quadruple therapy and longer treatment days have better eradication efficacies of H. pylori infection. (GUT 2018)
  • Our randomized trial found that the empirical guided therapy is not inferior to susceptibility guided therapy for treatment of refractory H. pylori infection (Gastroenterology 2018)
 
 

In 2019

  • The Vstrip®H. pylori antigen rapid test has been "pre-approved" by the US Food and Drug Administration. (Taiwan Panion & BF Biotech Inc.)
  • Our clinical trial showed that the short-term dysbiosis of gut microbiota after eradication ofH. pylori would recover gradually. (Lancet Infect Dis 2019)
  • The global consensus meeting for global gastric cancer prevention and treatment was held in Taipei in 2019.

In 2020

  • The Covid-19 detection equipment of the TCI CO., Ltd (QVS-96) was introduced and the Taiwan’s self-made medical equipment obtained the Emergency Use Authorization from the US FDA. (Nat Biotechnol 2020)
  • To confirm that large-scale community screening and H. pylorieradication can reduce the incidence of gastric cancer. (GUT 2020)
 
 

In 2021

  • To be invited to write an article discussing the relationship betweenH. pyloriand gut microbiota. (GUT microbes 2021)
  • The Maastricht consensus is considered to be the most important guideline for the clinical diagnosis and treatment ofH. pyloriinfection. The PI of our consortium, Professor Jyh-Ming Liu, was invited to be the leader of “Gastric cancer prevention” working group in 2021 Maastricht consensus meeting.
  • The PI was invited to write a review article in the top GI journal. (Clin Gastroenterol Hepatol 2021)

Members

TCTC

National Taiwan University Hospital

National Taiwan University Hospital

National Taiwan University Hospital

National Taiwan University Hospital

National Taiwan University Hospital

National Taiwan University Hospital

National Taiwan University Hospital

National Taiwan University HospitalNational Taiwan University Hospital

National Taiwan University Hospital

National Taiwan University Hospital

國立臺灣大學醫學院附設醫院

National Taiwan University Hospital

National Taiwan University Hospital, Yun-Lin Branch

National Taiwan University Hospital, Yun-Lin Branch

National Taiwan University Hospital, Yun-Lin Branch

National Taiwan University Hospital, Yun-Lin Branch

National Taiwan University Hospital, Yun-Lin Branch

Chia-yi Christian Hospital

Ditmanson Medical Foundation Chiayi Christian Hospital

Mackay Memorial Hospital, Taitung Branch

Kaohsiung Medical University Hospital

Fu-Jen Catholic University Hospital

China Medical University Hospital

E-Da Hospital, Kaohsiung

YANG-MING INSTITUTE OF BIOMEDICAL INFORMATICS

Contact Information

c-IRB

Professor Jyh-Ming, Liou

Email:jyhmingliou@gmail.com

TEL:(02)23123456 ext #63541